Analysts have been eager to weigh in on the Healthcare sector with new ratings on NanoString Tech (NSTG – Research Report), Aclaris Therapeutics (ACRS – Research Report) and Surface Oncology (SURF – Research Report).
NanoString Tech (NSTG)
Morgan Stanley analyst Tejas Savant maintained a Hold rating on NanoString Tech today and set a price target of $15.00. The company’s shares closed last Monday at $8.46.
According to TipRanks.com, Savant ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for NanoString Tech with a $14.33 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Aclaris Therapeutics (ACRS)
Goldman Sachs analyst Corinne Jenkins reiterated a Buy rating on Aclaris Therapeutics today. The company’s shares closed last Monday at $8.50.
According to TipRanks.com, Jenkins has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aclaris Therapeutics with a $28.75 average price target.
Surface Oncology (SURF)
JonesTrading analyst Soumit Roy maintained a Buy rating on Surface Oncology today and set a price target of $6.00. The company’s shares closed last Monday at $0.62, close to its 52-week low of $0.56.
According to TipRanks.com, Roy is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Surface Oncology with a $5.25 average price target, implying a 775.0% upside from current levels. In a report issued on May 4, Robert W. Baird also maintained a Buy rating on the stock with a $6.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NSTG:
